Prepare for RESI London and RESI JPM with Free Webinars on Fundraising and Partnering 

By Karen Deyo, VP of Product, Israel BD, LSN

karen-wpAs we approach RESI London and RESI JPM, Life Science Nation is offering a series of free webinars designed to help early-stage life science entrepreneurs refine their strategies and boost their chances of securing investor interest. These sessions will cover essential topics such as pitching techniques, partnering strategies, and insights from seasoned investors. Whether you’re new to fundraising or looking to enhance your current efforts, these webinars are tailored to equip you with the tools needed to navigate the funding landscape effectively. Sign up today and get ready to make the most of your RESI experience!

Tips on Pitching – Watch Recording

In the competitive world of early-stage startup funding, a compelling pitch can make or break your fundraising efforts. This webinar focuses on the art and science of crafting and delivering powerful investor presentations. Learn how to maximize your exposure to potential backers, refine your pitch for various audiences, and leverage pitch events to propel your early-stage life science fundraising campaign forward. Whether you’re a first-time founder or a seasoned entrepreneur, this session will equip you with the tools and strategies to captivate investors and secure the capital crucial for your venture’s growth.

October 24 – 12PM ET: LSN Partnering Event Process – Sign up

Attending partnering events is a crucial component of a successful fundraising campaign. Learn more about our proven successful strategy and how to craft your messages from your initial outreach and each follow-up message after that.

November 5 – 12PM ET: Investor Fireside Chat – Sign up

This Fireside Chat will feature investors representing funds focusing on early-stage life science companies. Find out more about these funds that play an active role in the LSN ecosystem.

November 12 – 10AM ET: Partnering Tutorial (RESI London) – Sign up

Understanding the RESI partnering system and using it to its maximum capabilities can greatly impact a company’s success at RESI. Join LSN staff as we walk you through our system and how it can help you identify partners who are the best fit for you, how to manage your outreach, our recommended strategy for following up, and how to take advantage of all of the content that we provide to ensure your best possible RESI experience.

November 21 – 12PM ET: Strategies on Fundraising and Finding Your Voice – Sign up

The most successful entrepreneurs are always the best storytellers. Finding a way to formulate your company’s unique story naturally and portraying it through multiple modalities, whether a 1-minute elevator pitch or a 12-slide pitch deck, is one of the most effective ways to get potential investors and partners on board with your value proposition. This bootcamp will cover the importance of entrepreneurial agency, finding your voice, and developing a compelling narrative for the different players that will emerge along a deal chain, and language tools to refine your hook.

December 3 – 12PM ET: Partnering Tutorial (RESI JPM) – Sign up

Understanding the RESI partnering system and using it to its maximum capabilities can greatly impact a company’s success at RESI. Join LSN staff as we walk you through our system and how it can help you identify partners who are the best fit for you, how to manage your outreach, our recommended strategy for following up, and how to take advantage of all of the content that we provide to ensure your best possible RESI experience.

December 12 – 12PM ET: Licensing and Partnering Strategies from Pharma – Sign up

This session will cover what Pharma companies use to determine their near and long-term strategy. What do they consider when deciding what indications and modalities are a priority? Partnering with Pharma requires an understanding of what they are seeking, and how a startup can fit into this strategy.

RESI-London-2024-1100px

RESI-SF-2025-Banner-1100px

Hot Investor Profile: Large Corporation With Life Science Focused Venture Arm Invests in Therapeutics, Diagnostics, and Digital Health Companies With Middle East Market Potential

A corporation with over 100 years of history and multibillion dollar assets under management has a venture arm that invests in healthcare. The venture arm will be contributing to investments in biotech companies in Series A and later stage companies. The goal of this venture arm is to bring new biotech innovation to Saudi Arabia and the Middle Eastern regions. Initial investments will range from $3M-5M in the form of a combination of equity and cash or non-diluted equity if the company has assets that could be leveraged in Saudi Arabia, which includes performing clinical research, manufacturing, and/or commercialization. The firm is predominantly interested in innovative therapeutics, digital health, and personalized diagnostics and with a preference for companies prioritizing US FDA and/or EMA approval. For therapeutics, the firm prefers clinical stage companies. For digital health and diagnostics, the firm prefers companies that have beta tested their product/platforms. 
 
Within therapeutics, the firm is focused on cell and gene therapy in Phase 2 and/or moving into Phase 3, with expectations for accelerated approvals. There are several indications of interest, including rare diseases, oncology, neurodegeneration, immunology, metabolic diseases, therapeutic vaccines, and regenerative therapeutics. Within digital health and diagnostics, the firm is primarily interested in technologies that are enterprise solutions, provider prescribed, personalized medicine or drug discovery engines. 
 
The firm is only interested in companies willing to work with Saudi Arabia toward the goal of bringing biotech innovation to the Gulf and Middle Eastern regions. Relocation is not required, however, a carveout or partnership at least in Saudi Arabia and other Gulf countries is necessary. The firm does not require a board seat but does prefer an observer seat after equity investment. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Profile: Pharma Corporate Venture Arm Invests in Therapeutics and Digital Technologies, With Strong Interests in Platform Technologies 

A corporate venture fund of a pharmaceutical company has their main office in the US. With its inaugural fund, the firm seeks to invest in technologies that are complementary to the parent pharma company’s R&D activities. The firm seeks to invest $5-7M as initial investment, and can invest up to $20M over the company’s lifecycle. The firm will focus on investing in companies based in the US, Western Europe, and Japan. 
 
The firm focuses on investing in therapeutics, platform technologies, and digital technologies. In therapeutics, the firm has a strong interest in cell/gene therapy, protein degraders, and covalent binders, as well as platform technologies including any platforms that can find or develop drugs across multiple therapeutic areas. Within digital technologies, the firm primarily seeks applications that help with target identification and drug design, accelerating drug discovery and development. The firm is not seeking clinical and patient-centric investments, and does not invest in medical devices or diagnostics. In terms of stage of development, the firm focuses on pre-clinical and early clinical stage opportunities. 
 
The firm does not have specific company or management team requirements. The firm does not lead investments and does not require board representation. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Profile: Newly Established VC Firm Seeks Seed Stage Companies in AI, Synthetic Biology, Cell/Gene Therapy Companies in the US 

A newly founded venture capital firm headquartered in the US is interested in Seed stage companies that focus on gene tech (DNA, RNA, proteins, and cells). Typical check size is expected to be around USD $500k and the firm will typically not lead rounds. Companies can have their headquarters elsewhere; however, the firm requires companies to be U.S. Incorporated. 
 
In terms of healthcare, the firm is interested in diagnostics using DNA, RNA, or proteins, cell and gene therapy, engineered vaccines, antibiotics, longevity and health span improvements, software and data, bioinformatic solutions, platforms, and AI-powered solutions. The firm is not interested in small molecules and medical devices. 

The firm does not have strict company or management team requirements. The firm does not require to take a board seat. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Profile: Europe-Based VC Firm Invests in Pre-Seed and Seed Stage AI-Driven Life Science and Healthcare Companies Across the Globe 

A venture capital headquartered in Europe was built on foundation of an incubator which has been operating since 2017. The firm invests in early-stage companies in the pre-seed and seed rounds, offering up to €250K tickets, with the possibility of follow-on investments. The firm invests globally, with a focus on European businesses. The firm offers convertibles and priced rounds, where the firm typically follows (or co-leads), and can assign a technical and business mentor to each team, tailoring the cooperation to the needs of each startup. 
 
The firm is sector-agnostic but exclusively focused on disruptive AI-driven solutions. The firm requires a testable prototype or proof-of-concept (POC) and initial business traction and is happy to look into B2B or B2C. 
 
The firm requires companies to have an established team of founders.  

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Profile: Global PE and VC Firm with UK & US Offices Invests Across Early to Late Stage Approaching IPO in Therapeutics, Healthcare, & Medtech Opportunities

A global private equity and venture capital firm with offices in the UK and the US has been investing in life sciences and healthcare for over 30 years and manages approximately $3.7 billion in AUM across several funds. The firm focuses on four key areas: therapeutics, dementia, healthcare growth, and medtech. For therapeutics, the firm is stage-agnostic and invests across all stages, from seed to crossover rounds approaching IPO. It also engages in company creation and building, allowing it to invest at very early stages in those cases. The average check size ranges from $5 million to $25 million, with the possibility of follow-on investments. While the firm prefers to lead, it is open to co-investing and will consider taking board positions on a case-by-case basis. As a transatlantic firm, the firm considers opportunities globally, with a focus on Europe and the US.

The firm invests in therapeutics, healthcare, and medtech. The therapeutics team is agnostic to both modalities and indications, considering a wide range of opportunities within the traditional therapeutics space. The firm is also stage-agnostic, investing at any stage from pre-clinical to late phases. In addition, the firm manages a separate fund which focuses exclusively on companies developing or enabling novel therapeutics for dementia.

The firm does not have specific requirements for the company or management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Profile: Corporate VC Arm of Global Dairy Corporation Seeks Seed to Series A Biotech Innovations for Human Health, Open to Various Deal Structures

An early-stage investment fund supporting innovation across human health, food, agriculture, and climate is backed by sole LP, one of the world’s largest dairy exporters and producer of human nutrition products. The fund brings experience and expertise across both investing & operating in the Food and BioTech, ClimateTech and AgTech sectors. Its operating model allows access into the nearly 100 years of capability, ingenuity, manufacturing and distribution experience within its parent corporation, while maintaining the agility and responsiveness to be a strong partner to start-ups and innovators in the space.

The fund typically invests in seed to Series A opportunities, though remains open to companies at later stages. The average check size ranges from $2M to $5M USD, with the ability to go beyond this. The fund is open to both leading and co-investing and will consider board positions on a case-by-case basis. The fund is actively seeking opportunities globally and is open to deal structures beyond equity investments, such as co-development and in-licensing, especially for technologies that align strategically with it parent corporation.

The fund is generally interested in technologies that use nutrients to improve human health, such as those targeting the microbiome, cognitive function, sleep, and more. Areas of interest include the microbiome, alternative ingredients, and the application of molecules and proteins. The fund places a strong emphasis on data. In terms of development stages, the fund is open to working with companies from the pre-clinical stage through all phases of clinical and commercial development. The fund does not have specific requirements for the company or management team. However, the fund seeks founding teams with passion and strong technical expertise.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.